Stocks

MRNA

Moderna

Biotechnology pioneer developing mRNA therapeutics, personalized oncology vaccines, and AI-assisted biologics.

Market data uses cached snapshots: prices refresh after 15 minutes, company details after 24 hours, and financials and corporate actions after 12 hours. Prices are completed-session closes, not live quotes.

Price snapshot retrieved . This is the retrieval time, not the trading-session time.

Some market snapshots are awaiting refresh or the provider is unavailable. Figures may be out of date; check the dates before using them.

$221.72
▼ 1.04 (-0.47%)
Close of · NASDAQ · Quotes are delayed at least 15 minutes.
12-month closing price

MRNA key data

Open
$220.53
Day range
$217.22 – $227.81
52-week range
$22.28 – $254.48
Volume
9.01M
Market cap
$88.52 billion
Shares outstanding
399.24M
Industry
Biological Products, (No Diagnostic Substances)
Employees
4,700

Dividends & corporate actions

  • Split — 1-for-10 on .
  • Split — 1-for-10 on .
  • Split — 1-for-4 on .

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna website

MRNA price chart

Daily open, high, low and close with volume.

Quotes are delayed at least 15 minutes.

MRNA technical indicators

Computed daily from MRNA's own price history — not third-party ratings. Technical analysis describes past price behaviour; it is information, not investment advice.

Technical Consensus Strong Bullish (6 Bull · 0 Neutral · 1 Bear)
RSI (14-day)
57.3 (Neutral)
20-day EMA
$210.47
50-day moving average
$182.49
200-day moving average
$86.58
200-day EMA
$102.92
Trend signal
Golden Cross (bullish long-term trend)
MACD (12, 26, 9)
Bearish (MACD below signal line)
Bollinger Bands (20-day)
$183.90 – $246.39
Stochastic %K (14-day)
56.3 (Neutral)
ATR (14-day)
$19.97

MRNA classic pivot support & resistance levels

Support 2 (S2)
$211.66
Support 1 (S1)
$216.69
Classic Pivot (P)
$222.25
Resistance 1 (R1)
$227.28
Resistance 2 (R2)
$232.84

Multi-horizon momentum & trend matrix

Timeframe Horizon Period Return Reference Moving Avg Horizon RSI Trend Posture
Short-Term (7-Period / EMA 20) -9.80% $210.47 (EMA 20) 56.3 Bullish
Medium-Term (30-Period / SMA 50) +43.94% $182.49 (SMA 50) 57.3 Bullish
Long-Term (90D–200D Macro) +266.96% $86.58 (SMA 200) 58.9 Bullish

Fibonacci retracement

Based on MRNA's high/low over the same history as the chart above.

0.0%
$254.48
23.6%
$199.68
38.2%
$165.78
50.0%
$138.38
61.8%
$110.98
78.6%
$71.97
100.0%
$22.28

MRNA annual investment, R&D and cash flow

Quarterly highlights and original SEC reports

Verified annual USD facts from SEC filings. Collected .

Annual period Revenue Cash capex Productive asset purchases Operating cash flow Free cash flow R&D R&D / revenue
to $1.94 billion $192 million Not available -$1.87 billion -$2.07 billion $3.13 billion 161.1%
RevenueFromContractWithCustomerExcludingAssessedTax · 10-K filed · accession 0001682852-26-000033
NetCashProvidedByUsedInOperatingActivities · 10-K filed · accession 0001682852-26-000033
PaymentsToAcquirePropertyPlantAndEquipment · 10-K filed · accession 0001682852-26-000033
ResearchAndDevelopmentExpense · 10-K filed · accession 0001682852-26-000033
to $3.24 billion $1.05 billion Not available -$3 billion -$4.06 billion $4.54 billion 140.4%
RevenueFromContractWithCustomerExcludingAssessedTax · 10-K filed · accession 0001682852-26-000033
NetCashProvidedByUsedInOperatingActivities · 10-K filed · accession 0001682852-26-000033
PaymentsToAcquirePropertyPlantAndEquipment · 10-K filed · accession 0001682852-26-000033
ResearchAndDevelopmentExpense · 10-K filed · accession 0001682852-26-000033
to $6.85 billion $707 million Not available -$3.12 billion -$3.83 billion $4.85 billion 70.8%
RevenueFromContractWithCustomerExcludingAssessedTax · 10-K filed · accession 0001682852-26-000033
NetCashProvidedByUsedInOperatingActivities · 10-K filed · accession 0001682852-26-000033
PaymentsToAcquirePropertyPlantAndEquipment · 10-K filed · accession 0001682852-26-000033
ResearchAndDevelopmentExpense · 10-K filed · accession 0001682852-26-000033
to $19.26 billion $400 million Not available $4.98 billion $4.58 billion $3.3 billion 17.1%
RevenueFromContractWithCustomerExcludingAssessedTax · 10-K filed · accession 0001682852-25-000022
NetCashProvidedByUsedInOperatingActivities · 10-K filed · accession 0001682852-25-000022
PaymentsToAcquirePropertyPlantAndEquipment · 10-K filed · accession 0001682852-25-000022
ResearchAndDevelopmentExpense · 10-K filed · accession 0001682852-25-000022
SEC filing data: definitions, coverage and revisions

Source: the SEC Company Facts API, using standard US GAAP facts in USD from annual 10-K, 20-F or 40-F filings and amendments. Periods must span 300-400 days. Quarterly and year-to-date values are not presented as annual totals.

  • Cash capex is cash payments to acquire property, plant and equipment. It excludes broader acquisition or intangible-asset tags and is not total AI spending or an estimate of finance-lease investment.
  • Productive asset purchases are a separately reported, broader cash investment measure. They are shown in their own column and never substituted into PP&E capex, capital intensity or free cash flow. Do not rank mixed definitions as if they were identical.
  • Free cash flow here is operating cash flow minus cash capex. It may differ from a company's adjusted free cash flow definition. If either input is missing, the result is omitted.
  • R&D intensity is reported research and development expense divided by revenue from the same annual reporting period. Operating cash margin and capital intensity use the same-period revenue denominator.
  • Figures are company-wide, not AI-specific or segment-level. Financial years differ, so compare the displayed start and end dates rather than assuming calendar-year alignment.
  • The latest available filing for each supported fact is used, including restated comparative figures. Conflicting values from equally recent reports are omitted. Every figure retains its XBRL tag, accession and filing date.

Company-specific extension tags, IFRS-only data and unsupported definitions are not estimated. Missing standard facts are shown as unavailable, not zero. Data is refreshed in the background; the collection time is separate from the filing date.

MRNA vs. related companies

Compare reported revenue growth, profitability and valuation. Related companies can have different business models and fiscal calendars.

Company Latest close Revenue growth (YoY) Net margin (TTM) P/E (TTM) P/S (TTM)
Moderna (MRNA) $221.72
 — — — —
Tesla (TSLA) $399.81
 — — — —
Robinhood (HOOD) $84.99
 — — — —

Related companies are drawn from our coverage universe and may operate in different industries. Prices reflect the latest available market close.

About the data and comparisons

Stock prices reflect the latest available market close. Market capitalisation and financial results may have different reporting dates; refer to the dates shown when comparing companies.

  • Revenue growth compares the latest fiscal quarter with the same fiscal quarter a year earlier. Missing or ambiguous comparison periods are not estimated.
  • TTM means trailing twelve months. Comparisons require four reported quarters with consistent USD units; unknown or other currencies are not converted or mixed. Net margin is TTM net income divided by TTM revenue.
  • P/E uses the displayed close divided by TTM diluted EPS and is omitted for non-positive earnings. P/S uses reference market capitalisation divided by positive TTM revenue; it is not enterprise value to sales.
  • Financial figures cover the whole company unless a business segment is specified. Inclusion in an AI theme does not indicate the share of revenue generated by AI.
  • Fiscal calendars and reporting dates differ. Check each row's period end and filing date before comparing. Missing values are shown as —, not zero; funds do not receive operating-company ratios.

Theme membership is editorial, not an investment recommendation or a complete market universe. Compare similar business models and verify financial statements through the company website linked on each stock page.

More on MRNA

No additional headlines in this cycle.

MRNA newsflow

Market-moving headlines mentioning Moderna.

All flash news

MRNA frequently asked questions

What is the MRNA stock price today?

Moderna (MRNA) last closed at $221.72 on October 30, 2026. Quotes are delayed at least 15 minutes.

What is the 52-week range for MRNA?

Over the past 52 weeks MRNA has traded between $22.28 and $254.48.

What is Moderna's market cap?

Moderna has a market capitalisation of about $88.52 billion.

Which exchange is MRNA listed on?

MRNA trades on NASDAQ, in the Biological Products, (No Diagnostic Substances) industry.

When did MRNA last split?

Moderna last executed a 1-for-10 stock split on August 3, 2017.

Where can I find the latest MRNA news?

Blockchain.News publishes MRNA coverage and price forecasts on this page, with 1 stories filed so far. This is information, not investment advice.

Is MRNA overbought or oversold?

MRNA's 14-day relative strength index (RSI) is 57.3, which is neutral on the standard 30/70 scale. RSI measures the speed of recent price moves, not a price target — this is not investment advice.

Is MRNA in an uptrend or downtrend?

MRNA's 50-day moving average is currently above its 200-day moving average — a Golden Cross (bullish long-term trend) in classic technical-analysis terms. Moving-average crossovers describe past price behaviour, not a forecast.

MRNA sectors

AI

Others in AI

NVDA MSFT GOOGL AMZN META AVGO AMD PLTR SMCI DELL ANET All AI →

Related stocks

TSLA HOOD

Coverage is for information only and is not investment advice. Stock prices can move quickly and past performance does not guarantee future results.

Quotes are delayed at least 15 minutes. Last updated .